Business
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 6–9, 2025, in Orlando, Florida.
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"Citius Oncology's LYMPHIR™ exhibit will be located at Booth #265","length":68,"tagName":"p","attribs":{}},{"type":"text","content":"LYMPHIR launch on track for Q4 2025","length":35,"tagName":"p","attribs":{}},{"type":"text","content":"CRANFORD, N.J., Nov. 25, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 6–9, 2025, in Orlando, Florida.","length":389,"tagName":"p"},{"type":"text","content":"The Citius Oncology team will be located at Booth #265 in the ASH Exhibit Hall to discuss LYMPHIR (denileukin diftitox-cxdl), its novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Company representatives will be available throughout the meeting to engage with physicians, researchers and the broader CTCL and oncology communities.","length":538,"tagName":"p"},{"type":"text","content":""We look forward to showcasing LYMPHIR at ASH 2025 and engaging directly with the oncology community," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharma. "This event offers a great platform to meet with CTCL stakeholders to discuss how LYMPHIR's clinical profile may offer an important treatment option for patients with cutaneous T-cell lymphoma."","length":416,"tagName":"p"},{"type":"text","content":"The ASH Annual Meeting is the world's premier event in malignant and non-malignant hematology, bringing together more than 25,000 clinicians, scientists, and industry leaders from around the globe. The meeting features cutting-edge research, expert education sessions, and an expansive exhibit hall showcasing the latest advances in hematologic innovation.","length":360,"tagName":"p"},{"type":"text","content":"About LYMPHIR™ (denileukin diftitox-cxdl)","length":41,"tagName":"p"},{"type":"text","content":"LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated f...